Patient preferences for oral versus intravenous palliative chemotherapy

被引:774
作者
Liu, G
Franssen, E
Fitch, MI
Warner, E
机构
[1] TORONTO SUNNYBROOK REG CANC CTR, DEPT MED ONCOL, DIV ONCOL, N YORK, ON M4N 3M5, CANADA
[2] UNIV TORONTO, TORONTO, ON, CANADA
关键词
D O I
10.1200/JCO.1997.15.1.110
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To assess patient preference for oral versus intravenous (IV) palliative chemotherapy (CT), A strong preference would be an important quality-of-life issue. Patients and Methods: A structured interviewer-administered scenario;based questionnaire evaluated incurable cancer patients who would be likely to receive palliative CT in the future, Using probability trade-offs, the preference far route of administration was evaluated against diminishing treatment response. Results: Of 103 assessable patients, 92 preferred oral CT, 10 preferred IV CT, and one had no preference. patient preferences were not associated with age, sex, site of primary cancer, or previous CT experiences, Major reasons for preferring oral Cf were convenience, problems with IV access or needles, and a better CT-taking environment (outside of the clinic), Regardless of initial preference, 70% of patients were not willing to accept a lower response rare and 74% were not willing to accept a shorter duration of response to retain their initial preference, Although 99% of patients had a preference, 39% wanted the specific treatment decision made primarily by their physicians, 38% primarily by themselves, and 22% shared equally. Conclusion: patients with incurable cancer have a clear preference for oral CT, are generally not willing to sacrifice efficacy for their preference, Almost 40% of patients did not want to make final treatment decisions themselves. (C) 1997 by American Society of Clinical Oncology.
引用
收藏
页码:110 / 115
页数:6
相关论文
共 40 条
[1]  
BORST CG, 1992, CANC NURS, P378
[2]   IMPLANTABLE CENTRAL VENOUS ACCESS SYSTEM [J].
BOTHE, A ;
PICCIONE, W ;
AMBROSINO, JJ ;
BENOTTI, PN ;
LOKICH, JJ .
AMERICAN JOURNAL OF SURGERY, 1984, 147 (04) :565-569
[3]  
CARNEY DN, 1991, CANCER, V67, P299, DOI 10.1002/1097-0142(19910101)67:1+<299::AID-CNCR2820671315>3.0.CO
[4]  
2-K
[5]  
CLAESSEN KA, 1990, NETH J SURG, V42, P47
[6]   ON THE RECEIVING END PATIENT PERCEPTION OF THE SIDE-EFFECTS OF CANCER-CHEMOTHERAPY [J].
COATES, A ;
ABRAHAM, S ;
KAYE, SB ;
SOWERBUTTS, T ;
FREWIN, C ;
FOX, RM ;
TATTERSALL, MHN .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (02) :203-208
[7]   PATIENTS CHOICES AND PERCEPTIONS AFTER AN INVITATION TO PARTICIPATE IN TREATMENT DECISIONS [J].
ENGLAND, SL ;
EVANS, J .
SOCIAL SCIENCE & MEDICINE, 1992, 34 (11) :1217-1225
[8]  
GOUGH IR, 1991, CANCER, V68, P220, DOI 10.1002/1097-0142(19910701)68:1<220::AID-CNCR2820680140>3.0.CO
[9]  
2-H
[10]   CHRONIC DAILY ADMINISTRATION OF ORAL ETOPOSIDE IN REFRACTORY LYMPHOMA [J].
HAINSWORTH, JD ;
JOHNSON, DH ;
FRAZIER, SR ;
GRECO, FA .
EUROPEAN JOURNAL OF CANCER, 1990, 26 (07) :818-821